Clinical Trial Update: Anlotinib In Combination With RFA And TACE in Patients With Middle-advanced HCC [Phase 2]

View source ↗

Summary

Phase 2 clinical trial exploring anlotinib in combination with radiofrequency ablation (RFA) and transarterial chemoembolization (TACE) for hepatocellular carci…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Anlotinib (anlotinib)

Snippet

Sponsor: Jinglong Chen | Conditions: Hepatocellular Carcinoma | Phase 2 | Status: UNKNOWN